T1	Participants 225 290	patients with advanced gastric or gastroesophageal cancer (AGGEC)
T2	Participants 129 187	advanced gastric or gastroesophageal cancer adenocarcinoma
T3	Participants 545 557	445 patients
T4	Participants 1838 1852	AGGEC patients
